相关实验视频
Updated: Jun 26, 2025
08:56
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
Published on: April 7, 2023
873
在老年痴呆症患者中,β-阻断剂对骨的保护作用
Khiem Khuc1, Jude des Bordes1, Abayomi Ogunwale1
1Department Family and Community Medicine, UTHealth McGovern Medical School, Houston, TX, USA.
Calcified tissue international
|May 14, 2024
概括
使用β-阻断剂可能会减缓老年痴呆症男性的骨质损失. 这项研究发现,与非使用者相比,β阻断剂使用者在股骨部的骨矿物质密度损失较少.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 骨的新陈代谢 骨的新陈代谢
背景情况:
- 增加β-上腺素受体活性与痴呆症患者的骨质损失有关.
- β-抑制剂是常见的药物,影响β-上腺素受体活性.
研究的目的:
- 调查长期使用β-阻断剂对老年痴呆症患者骨损失率的影响.
- 为了确定β-阻断剂是否对这一群体的骨矿物质密度有保护作用.
主要方法:
- 利用线性混合效应模型来分析来自健康衰老和身体组成研究的数据.
- 检查了1198名参与者的记录,重点关注痴呆症状况,β阻断剂的使用和骨矿物质密度 (BMD) 变化.
- 专门分析了痴呆症男性和女性的子组.
主要成果:
- 在患有痴呆症的男性中,β-阻断剂使用者与非使用者 (p <0.05) 相比,在股骨部的骨损失显著减缓 (每年减少0.00491 g/cm2,或每年减少0.63%).
- 在患有或没有痴呆症的女性中,或在没有痴呆症的男性中,没有观察到骨损失率的显著差异.
- 少数患有痴呆症的参与者服用β-阻断剂 (23名男性,15名女性).
结论:
- β抑制剂可能通过减缓痴呆症老年男性的骨质损失提供保护作用.
- 需要进一步的研究来证实这些发现,并探索潜在的机制.
- 这些发现表明,β阻断剂对特定痴呆症患者群体的骨健康有潜在的治疗益处.
相关概念视频
01:29Bone Disorders
3.5K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.5K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
757
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
757
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:28Antihypertensive Drugs: Types of β-Blockers
654
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
654
01:17Antihypertensive Drugs: Action of β1 Blockers
432
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
432
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
439
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
439